Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery


ABSTRACT

BACKGROUND
Prophylactic administration of tranexamic acid has been associated with reduced postpartum blood loss after cesarean delivery in several small trials, but evidence of its benefit in this clinical context remains inconclusive.

METHODS
In a multicenter, double-blind, randomized, controlled trial, we assigned women undergoing cesarean delivery before or during labor at 34 or more gestational weeks to receive an intravenously administered prophylactic uterotonic agent and either tranexamic acid (1 g) or placebo. The primary outcome was postpartum hemorrhage, defined as a calculated estimated blood loss greater than 1000 ml or receipt of a red-cell transfusion within 2 days after delivery. Secondary outcomes included gravimetrically estimated blood loss, provider-assessed clinically significant postpartum hemorrhage, use of additional uterotonic agents, and postpartum blood transfusion.

RESULTS
Of the 4551 women who underwent randomization, 4431 underwent cesarean delivery, 4153 (93.7%) of whom had primary outcome data available. The primary outcome occurred in 556 of 2086 women (26.7%) in the tranexamic acid group and in 653 of 2067 (31.6%) in the placebo group (adjusted risk ratio, 0.84; 95% confidence interval [CI], 0.75 to 0.94; P=0.003). There were no significant between-group differences in mean gravimetrically estimated blood loss or in the percentage of women with provider-assessed clinically significant postpartum hemorrhage, use of additional uterotonic agents, or postpartum blood transfusion. Thromboembolic events in the 3 months after delivery occurred in 0.4% of women (8 of 2049) who received tranexamic acid and in 0.1% of women (2 of 2056) who received placebo (adjusted risk ratio, 4.01; 95% CI, 0.85 to 18.92; P=0.08).

CONCLUSIONS
Among women who underwent cesarean delivery and received prophylactic uterotonic agents, tranexamic acid treatment resulted in a significantly lower incidence of calculated estimated blood loss greater than 1000 ml or red-cell transfusion by day 2 than placebo, but it did not result in a lower incidence of hemorrhage-related secondary clinical outcomes. (Fundied by the French Ministry of Health; TRAAP2 ClinicalTrials.gov number, NCT03431805.)
Postpartum Hemorrhage Remains a Leading Cause of Severe Maternal Complications and Death Worldwide.1 Prophylactic administration of a uterotonic agent is recommended to reduce the risk of postpartum hemorrhage.2-4 Tranexamic acid has emerged in the past decade as another candidate drug to prevent blood loss after childbirth. Tranexamic acid has antifibrinolytic effects that are achieved at least in part by promotion of hemostasis through the blocking of lysine-binding sites on plasminogen molecules, and evidence of its clinical effects has been found in various contexts.5-6 In clinical trials outside of obstetrics, tranexamic acid has been found to reduce the need for transfusions in elective surgery7,8 and to reduce mortality among patients with extracranial9 or mild-to-moderate intracranial trauma.10 Tranexamic acid also reduces bleeding-related mortality among women with postpartum hemorrhage11 and is consequently recommended worldwide for these patients.12,13 Moreover, the survival benefit associated with the earlier administration of the drug in these women14 suggests that it may prevent coagulopathy after delivery rather than treat it.4,5,14

We examined the effect of prophylactic tranexamic acid at vaginal delivery in a previous trial published in the Journal and found no significant effect on the incidence of blood loss of at least 500 ml in women who also received a prophylactic uterotonic agent.15 Small, single-center, randomized, controlled trials have shown significantly reduced blood loss when prophylactic tranexamic acid is given to women undergoing elective cesarean delivery.4,6 Nevertheless, because of methodologic limitations related to blinding, outcome assessment, attrition bias, and absence of postdischarge follow-up, especially for thromboembolic events, the findings in these trials are interpreted as inconclusive.4,6,16,17 and current guidelines do not advocate routine administration of tranexamic acid after cesarean deliveries.4,11 We designed this trial to investigate whether tranexamic acid plus a prophylactic uterotonic agent would be associated with a lower incidence of postpartum hemorrhage after cesarean delivery than the uterotonic agent alone.

METHODS

TRIAL DESIGN

We conducted the Tranexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery (TRAAP2) trial, a multicenter, randomized, placebo-controlled, double-blind trial with two parallel groups that was modeled on our previous trial of tranexamic acid after vaginal delivery (TRAAP trial).15,18 Women who were expected to undergo a cesarean delivery were randomly assigned to receive a uterotonic agent plus either tranexamic acid or placebo immediately after delivery. Details of the rationale and design of the trial have previously been published,19 and the protocol and statistical analysis plan are available with the full text of this article at NEJM.org.

The trial protocol was approved by the Northwest VI Committee for the Protection of Research Subjects and the French National Agency of Medicine and Health Products Safety. The first, last, and fourth-to-last authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol and statistical analysis plan. No company or manufacturer was involved in the trial.

PARTICIPANTS

Women were eligible to participate if they were 18 years of age or older with a singleton or multiple pregnancy at 34 or more weeks of gestation and were expected to undergo cesarean delivery before or during labor. They were recruited at 27 French maternity hospitals. Women with a known or possible increased risk of venous or arterial thrombosis or of bleeding, a history of epilepsy or seizure, a prenatal hemoglobin level of 9 g per deciliter or lower in the week before delivery, or poor comprehension of spoken French were not eligible (details of the exclusion criteria are provided in Table S1 in the Supplementary Appendix, available at NEJM.org).19 Caregivers (physicians or midwives) provided information about the trial individually to each woman during late pregnancy. Women confirmed participation and provided written informed consent only if the investigator considered cesarean delivery to be likely.

RANDOMIZATION AND PROCEDURES

Eligible women who had provided consent were randomly assigned in a 1:1 ratio to receive either 1 g of tranexamic acid (purchased at full cost from Sanofi Aventis) or placebo (normal saline, Fresenius Kabi). Computerized randomization (in blocks of four) was performed centrally through a secure Internet facility (Ennov Clinical Software) and was stratified according to trial site and timing of cesarean delivery (before or...
during labor). The randomization procedure was supervised at Bordeaux University Hospital, and information on each randomization was transmitted to the PRIRIGO (Production Pharmaceutique pour la Recherche Institutionnelle du Grand Ouest) hospital pharmacists’ consortium, which prepared the ampules of tranexamic acid or placebo. The products were prepared in numbered and labeled boxes, each containing a 10-ml vial of either tranexamic acid (1 g) or placebo, depending on the randomization number. All boxes and vials were identical and labeled and were differentiated only by their randomization numbers. Neither the participants nor the investigators were aware of the group assignments during the trial.

Clinicians were instructed to administer tranexamic acid or placebo intravenously over a period of 30 to 60 seconds during the 3 minutes after birth, after the prophylactic uterotonic agent (5 or 10 IU of oxytocin or 100 μg of carbocetin) had been administered and the cord had been clamped. Administration of the prophylactic uterotonic agent (and tranexamic acid or placebo) may have been followed by a 2-hour oxytocin infusion, in accordance with the policy at each center. All these aspects of management had been clamped. Administration of the prophylactic uterotonic agent (and tranexamic acid or placebo) may have been followed by a 2-hour oxytocin infusion, in accordance with the policy at each center. All these aspects of management of the third stage of labor were standardized at each center and adhered to national guidelines, including the possibility of administering tranexamic acid if postpartum hemorrhage occurred.20

After cesarean delivery, women were transferred from the operating room to the postanesthesia care unit (PACU), where they stayed for at least 2 hours, until the birth attendant considered that bleeding had diminished to the normally expected amount. Gravimetrically estimated blood loss was assessed. A venous blood sample was obtained on day 2 after delivery for outcome assessment. Adverse events were assessed until hospital discharge and by telephone interview at 3 months after delivery, given the increased thromboembolic risk during the 3-month period after delivery.21

OUTCOMES
The primary outcome was postpartum hemorrhage, defined as a calculated estimated blood loss greater than 1000 ml or a red-cell transfusion within 2 days after delivery.22 The estimated blood loss was calculated as the estimated blood volume × (preoperative hematocrit – postoperative hematocrit) ÷ preoperative hematocrit; the estimated blood volume in milliliters was calculated as the body weight in kilograms × 85.22,23 We chose this quantitative objective estimate of blood loss because of the limited accuracy of blood-loss estimation for cesarean deliveries when other, subjective methods are used.20 Preoperative hematocrit was the value most recently measured within 8 days before delivery, and postoperative hematocrit was that measured closest to day 2 after delivery (without transfusion).

Secondary outcomes included clinical and laboratory (blood samples at day 2) measurements of postpartum blood loss,24–26 adverse events that were assessed by the investigators as being potentially related to tranexamic acid, maternal satisfaction on day 2, and psychological status at 2 months, assessed with the Edinburgh Postnatal Depression Scale (EPDS).29 These secondary outcomes belong to the consensus core outcome set for studies evaluating interventions for the prevention and treatment of postpartum hemorrhage30 and are described in detail in Table S2.19

The physician responsible for the delivery prospectively recorded the procedures used during the third stage of labor and clinical outcomes identified in the immediate postpartum period. Research assistants who were independent of the local medical team obtained all other data from medical charts.

STATISTICAL ANALYSIS
We based the expected incidence of the primary outcome on results in the placebo group in previous studies,22,31 in particular the Elective Cesarean Section Syntocinon (oxytocin) Infusion Trial (ECSSIT),22 and estimated that 4072 women undergoing cesarean delivery would provide power of at least 80% to detect a relative difference of 20% or greater in the incidence of the primary outcome (i.e., 15% in the placebo group and 12% in the tranexamic acid group), with a 5% two-sided type 1 error. Given the expected percentage of women who would deliver vaginally, be lost to follow-up, or lack the blood samples needed for the assessment of the primary outcome (estimated at a maximum of 10%), we aimed to enroll 4524 women in order to include the needed number of women undergoing a cesarean delivery with available data for assessment of the primary outcome.

The main analysis of the primary and secondary outcomes was performed in the modified intention-to-treat population, which included all women who underwent randomization and had
a cesarean delivery, with the exception of those who withdrew consent or were determined to be ineligible after randomization. The safety population included all women who received tranexamic acid or placebo. We also analyzed two per-protocol populations, which included women from the modified intention-to-treat population who received a uterotonic agent and then tranexamic acid or placebo within 3 minutes after birth (per-protocol 1 population) or within 10 minutes after birth (per-protocol 2 population), as prespecified in the protocol; the latter situ-
The primary outcome analysis was conducted with multiple imputation by fully conditional specification to take missing values into account. We performed sensitivity analyses of the primary outcome first by imputing missing values as failures and then by using complete cases. Secondary analyses were conducted with available data.

Participants’ baseline characteristics, management of the third stage of labor, and protocol adherence are provided as descriptive data; qualitative variables are expressed as percentages and quantitative variables as either means with standard deviations or medians with interquartile ranges, as appropriate. The effects of tranexamic acid are expressed as risk ratios with 95% confidence intervals for categorical outcomes estimated with Poisson mixed-effects models and as mean differences with 95% confidence intervals for quantitative outcomes estimated with linear mixed-effects models; all models were adjusted for center and timing of cesarean delivery (before or during labor).

Two prespecified subgroup analyses were used to test the effect of tranexamic acid on the
Table 2. Primary and Secondary Outcomes in the Modified Intention-to-Treat Population.*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Tranexamic Acid Group (N = 2222)</th>
<th>Placebo Group (N = 2209)</th>
<th>Unadjusted Difference (95% CI)†</th>
<th>Adjusted Risk Ratio or Mean Difference (95% CI)‡</th>
<th>P Value§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postpartum hemorrhage — no./total no. (%)¶</td>
<td>556/2086 (26.7)</td>
<td>653/2067 (31.6)</td>
<td>-9.4 (-17.7 to -2.2)</td>
<td>0.84 (0.75 to 0.94)</td>
<td>0.003</td>
</tr>
<tr>
<td>Calculated estimated blood loss &gt;1000 ml</td>
<td>550/2084 (26.4)</td>
<td>650/2066 (31.5)</td>
<td>-5.1 (-7.8 to -2.3)</td>
<td>0.84 (0.75 to 0.94)</td>
<td>—</td>
</tr>
<tr>
<td>Red-cell transfusion by day 2</td>
<td>35/2221 (1.6)</td>
<td>30/2209 (1.4)</td>
<td>0.2 (-0.5 to 0.9)</td>
<td>1.16 (0.71 to 1.89)</td>
<td>—</td>
</tr>
<tr>
<td>Gravimetrically estimated blood loss — ml‖</td>
<td>689±887</td>
<td>719±920</td>
<td>-30.6 (-90.2 to 29.0)</td>
<td>-33.06 (-77.48 to 11.37)</td>
<td>NS</td>
</tr>
<tr>
<td>Gravimetrically estimated blood-loss category — no./total no. (%)‖</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;500 ml</td>
<td>1133/1774 (63.9)</td>
<td>1110/1754 (63.3)</td>
<td>0.6 (-2.6 to 3.8)</td>
<td>1.01 (0.93 to 1.09)</td>
<td>—</td>
</tr>
<tr>
<td>&gt;1000 ml</td>
<td>545/1774 (30.7)</td>
<td>521/1754 (29.7)</td>
<td>1 (-2 to 4)</td>
<td>1.03 (0.92 to 1.16)</td>
<td>—</td>
</tr>
<tr>
<td>Clinically significant postpartum hemorrhage according to health care providers — no./total no. (%)</td>
<td>303/2220 (13.6)</td>
<td>327/2208 (14.8)</td>
<td>-1.2 (-3.2 to 0.9)</td>
<td>0.92 (0.79 to 1.08)</td>
<td>NS</td>
</tr>
<tr>
<td>Additional uterotonic agents for excessive bleeding — no./total no. (%)</td>
<td>130/2217 (5.9)</td>
<td>159/2206 (7.2)</td>
<td>-1.3 (-2.8 to 0.1)</td>
<td>0.81 (0.64 to 1.03)</td>
<td>NS</td>
</tr>
<tr>
<td>Blood transfusion — no./total no. (%)</td>
<td>42/2221 (1.9)</td>
<td>39/2208 (1.8)</td>
<td>0.1 (-0.7 to 0.9)</td>
<td>1.07 (0.69 to 1.66)</td>
<td>NS</td>
</tr>
<tr>
<td>No. of red-cell units transfused</td>
<td>3.1±1.9</td>
<td>3.2±2.2</td>
<td>-0.1 (-1.0 to -0.08)</td>
<td>-0.08 (-1.18 to 1.01)</td>
<td>—</td>
</tr>
<tr>
<td>Postoperative iron sucrose infusion — no./total no. (%)</td>
<td>60/2196 (2.7)</td>
<td>44/2185 (2.0)</td>
<td>0.7 (-0.2 to 1.6)</td>
<td>1.35 (0.91 to 1.99)</td>
<td>—</td>
</tr>
<tr>
<td>Arterial embolization, emergency surgery for postpartum hemorrhage, or hysterectomy — no./total no. (%)**</td>
<td>13/2221 (0.6)</td>
<td>7/2209 (0.3)</td>
<td>0.3 (-0.1 to 0.7)</td>
<td>1.84 (0.73 to 4.62)</td>
<td>NS</td>
</tr>
<tr>
<td>Transfer to intensive care unit — no./total no. (%)</td>
<td>32/2221 (1.4)</td>
<td>22/2209 (1.0)</td>
<td>0.4 (-0.2 to 1.1)</td>
<td>1.44 (0.83 to 2.47)</td>
<td>—</td>
</tr>
<tr>
<td>Calculated estimated blood loss — ml††</td>
<td>680±748</td>
<td>787±750</td>
<td>-107 (-152 to -61)</td>
<td>-107 (-152 to -63)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Calculated estimated blood loss category — no./total no. (%)††</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;500 ml</td>
<td>1213/2084 (58.2)</td>
<td>1326/2066 (64.2)</td>
<td>-6.0 (-8.9 to -3.0)</td>
<td>0.91 (0.84 to 0.98)</td>
<td>—</td>
</tr>
<tr>
<td>&gt;1500 ml</td>
<td>215/2084 (10.3)</td>
<td>263/2066 (12.7)</td>
<td>-2.4 (-4.4 to -0.5)</td>
<td>0.81 (0.68 to 0.97)</td>
<td>—</td>
</tr>
<tr>
<td>Hemoglobin‡‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripartum change — g/dl — no./total no. (%)</td>
<td>-1.2±1.2</td>
<td>-1.4±1.2</td>
<td>0.2 (0.1 to 0.3)</td>
<td>0.18 (0.11 to 0.25)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peripartum decrease &gt;2 g/dl — no./total no. (%)</td>
<td>397/2088 (19.0)</td>
<td>497/2071 (24.0)</td>
<td>-5.0 (-7.5 to -2.5)</td>
<td>0.79 (0.69 to 0.90)</td>
<td>—</td>
</tr>
<tr>
<td>Hematocrit††</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripartum change — percentage points</td>
<td>-3.5±3.7</td>
<td>-4.0±3.7</td>
<td>0.5 (0.3 to 0.8)</td>
<td>0.53 (0.31 to 0.75)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peripartum decrease &gt;10 percentage points — no./total no. (%)</td>
<td>66/2086 (3.2)</td>
<td>93/2071 (4.5)</td>
<td>-1.3 (-2.5 to -0.2)</td>
<td>0.70 (0.51 to 0.97)</td>
<td>—</td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. No hypovolemic shock or maternal death occurred in either group. Data on gravimetrically estimated blood loss were not available for 448 women in the tranexamic acid group and 455 in the placebo group; on red-cell units transfused for 2180 and 2170, respectively; on calculated estimated blood loss for 138 and 143, respectively; on peripartum change in hemoglobin level for 134 and 138, respectively; and on peripartum change in hematocrit for 136 and 138, respectively. NS denotes not significant (in accordance with the Benjamini–Hochberg procedure).
adjusted for multiple testing with the use of the Benjamini–Hochberg procedure; for outcomes for which the difference was not tested in accordance with the statistical analysis plan (details are provided in Table S6).

‡‡ Preoperative hemoglobin was defined as the most recent hemoglobin level measured in the 8 days before delivery, and postpartum hemoglobin was defined as the measurement closest to day 2. For patients who received a transfusion before the blood sample was obtained, the value of the postpartum hemoglobin was calculated as the value of the hemoglobin at day 2 (in grams per deciliter) − (1 × number of units of red cells transfused) (details are provided in Table S2).

Results

From March 2018 through January 2020, we enrolled 4551 eligible participants and randomly assigned them to receive tranexamic acid (2276 women) or placebo (2275); 112 women were excluded because they withdrew consent or were found to be ineligible after randomization. Of the remaining 4439 women (intention-to-treat population), 8 had a vaginal delivery; therefore, the modified intention-to-treat population included 4431 women (2222 in the tranexamic acid group and 2209 in the placebo group) (Fig. 1). The baseline characteristics of the women, protocol adherence, and other aspects of management of the third stage of labor were similar in the two groups (Tables 1 and S4).

Primary Outcome

Data on the primary outcome were missing for 136 women in the tranexamic acid group and for 142 in the placebo group because preopera-
tive or postoperative hematocrit or maternal weight was not available. Postpartum hemorrhage, defined as a calculated estimated blood loss greater than 1000 ml or red-cell transfusion by day 2, occurred in 556 of 2086 women (26.7%) in the tranexamic acid group and in 653 of 2067 (31.6%) in the placebo group (adjusted risk ratio, 0.84; 95% confidence interval [CI], 0.75 to 0.94; P=0.003 with multiple imputation of missing values) (Table 2). Sensitivity analyses with missing values imputed as failures and with complete cases yielded similar results (Table S5).

Figure 2 shows the results of the subgroup analyses. There was no evidence of differential effects of tranexamic acid according to the timing of cesarean delivery (before or during labor) or the presence or absence of known risk factors for postpartum hemorrhage.

SECONDARY OUTCOMES

There were no significant between-group differences in the incidence of any of the following hemorrhage-related clinical outcomes: mean gravimetrically estimated blood loss, provider-assessed clinically significant hemorrhage, use of additional uterotonic agents for excessive bleeding, postpartum blood transfusion, and arterial embolization or emergency surgery. However, the mean calculated estimated blood loss and mean peripartum changes in hemoglobin and hematocrit were lower in the tranexamic acid group than in the placebo group (adjusted P<0.001 for all three comparisons) (Tables 2 and S6). No significant between-group differences were observed for systolic, mean, or diastolic blood pressure after delivery (Fig. S1).

ADVERSE EVENTS

Table 3 shows safety-related outcomes (additional details are provided in Tables S7 and S8). The incidence of vomiting or nausea in the operating room or PACU was higher in the tranexamic acid group than in the placebo group (43.0% vs. 36.3%, adjusted P<0.001). There were no significant between-group differences in prothrombin time, activated partial thromboplastin time, ami-notransferase levels, fibrinogen level, or kidney-function tests on day 2. At 3 months after delivery, data on adverse events were available for 94.0% of the women. During this period, thromboembolic events had occurred in 0.4% (8 of 2049) of the women in the safety population who received tranexamic acid and in 0.1% (2 of 2056) of those who received placebo (adjusted risk ratio, 4.01; 95% CI, 0.85 to 18.92; P=0.08).

MATERNAL SATISFACTION, PSYCHOLOGICAL STATUS, AND PER-PROTOCOL ANALYSES

There was no evidence of differences between the groups in maternal satisfaction at day 2 and EPDS scores at 2 months (Tables S9 and S10). Analyses of the primary and secondary outcomes in the per-protocol populations showed results similar to those in the modified intention-to-treat population (Tables S11 through S14).

![Figure 2. Prespecified Subgroup Analyses of the Primary Outcome (Modified Intention-to-Treat Population).](image)

Shown is the risk ratio for postpartum hemorrhage (PPH) (tranexamic acid vs. placebo), adjusted for randomization stratification variables (center and timing of the cesarean delivery). PPH was defined as a calculated estimated blood loss greater than 1000 ml or receipt of a red-cell transfusion within 2 days after delivery. Women who were at risk for PPH were defined as those who had one or more risk factors for PPH with an odds ratio of at least 3 in the literature\(^3\): previous PPH, pregnancy-related hypertensive disorder, multiple pregnancy, or cesarean delivery during labor.

DISCUSSION

Among women who underwent cesarean delivery and received a prophylactic uterotonic agent, the use of tranexamic acid resulted in a significantly lower incidence of the primary outcome — calculated estimated blood loss greater than 1000 ml or red-cell transfusion by day 2 — than did the use of placebo. However, the use of tranexamic acid did not result in lower incidences of clinical secondary outcomes related to blood loss than placebo.

Our results show that prophylactic use of tranexamic acid at cesarean delivery had a biologic effect, in that the calculated estimated blood loss was significantly lower among women who received the drug than among those who received placebo (the mean between-group difference...
Table 3. Adverse Events (Safety Population). *

<table>
<thead>
<tr>
<th>Event or Measure</th>
<th>Tranexamic Acid Group (N = 2190)</th>
<th>Placebo Group (N = 2177)</th>
<th>Unadjusted Difference (95% CI)†</th>
<th>Adjusted Risk Ratio or Mean Difference (95% CI)‡</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unadjusted</td>
<td>Adjusted§</td>
<td></td>
</tr>
<tr>
<td>In the operating room or PACU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting or nausea — no. (%)</td>
<td>940/2186 (43.0)</td>
<td>786/2166 (36.3)</td>
<td>6.7 (3.8 to 9.6)</td>
<td>1.19 (1.08 to 1.30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Photopsia — no. (%)¶</td>
<td>8/2186 (0.4)</td>
<td>2/2166 (0.1)</td>
<td>0.3 (0.0 to 0.6)</td>
<td>3.92 (0.83 to 18.45)</td>
<td>—</td>
</tr>
<tr>
<td>Dizziness — no. (%)</td>
<td>93/2186 (4.3)</td>
<td>68/2166 (3.1)</td>
<td>1.1 (0.0 to 2.2)</td>
<td>1.35 (0.99 to 1.85)</td>
<td>—</td>
</tr>
<tr>
<td>Day 2 after delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea nitrogen — mmol/liter</td>
<td>3.5±1.6</td>
<td>3.5±1.5</td>
<td>0.0 (−0.1 to 0.1)</td>
<td>0.03 (−0.06 to 0.13)</td>
<td>0.47 NS</td>
</tr>
<tr>
<td>Creatinine — μmol/liter</td>
<td>55.1±12.1</td>
<td>55.6±11.3</td>
<td>−0.5 (−1.2 to 0.3)</td>
<td>−0.41 (−1.11 to 0.30)</td>
<td>0.26 NS</td>
</tr>
<tr>
<td>Alanine aminotransferase &gt;2× ULN — no. (%)</td>
<td>26/2042 (1.3)</td>
<td>19/2043 (0.9)</td>
<td>0.3 (−0.3 to 1.0)</td>
<td>1.37 (0.76 to 2.48)</td>
<td>0.29 NS</td>
</tr>
<tr>
<td>Aspartate aminotransferase &gt;2× ULN — no. (%)</td>
<td>32/2047 (1.6)</td>
<td>34/2039 (1.7)</td>
<td>−0.1 (−0.9 to 0.7)</td>
<td>0.94 (0.58 to 1.52)</td>
<td>0.79 NS</td>
</tr>
<tr>
<td>Up to 3 mo after delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completed interviews at 3 mo — no. (%)</td>
<td>2047/2190 (93.5)</td>
<td>2056/2177 (94.4)</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Deep-vein thrombosis or pulmonary embolism — no. (%)</td>
<td>8/2049 (0.4)††</td>
<td>2/2056 (0.1)</td>
<td>0.3 (0.0 to 0.6)</td>
<td>4.01 (0.85 to 18.92)</td>
<td>0.08 NS</td>
</tr>
<tr>
<td>Seizure — no. (%)‡‡</td>
<td>1/2047 (&lt;0.1)</td>
<td>1/2054 (&lt;0.1)</td>
<td>—</td>
<td>—</td>
<td></td>
</tr>
</tbody>
</table>

* Plus–minus values are means ±SD. The safety population included 2190 women who received tranexamic acid (2187 who had been randomly assigned to the tranexamic acid group and 3 who had been randomly assigned to the placebo group), and 2177 women who received placebo (2 who had been randomly assigned to the tranexamic acid group and 2175 who had been randomly assigned to the placebo group). No retinal vascular occlusion, myocardial infarction, or kidney failure treated with dialysis occurred in either group. PACU denotes postanesthesia care unit, and ULN upper limit of the normal range.
† Differences between percentages are presented in percentage points, and differences between mean values are given in the units of the mean values.
‡ Adjusted risk ratios and adjusted mean differences were estimated with the use of Poisson mixed-effects regression models and linear mixed-effects models, respectively, with systematic adjustment for randomization stratification variables (center and timing of cesarean delivery [before or during labor]).
§ P values were adjusted for multiple testing with the use of the Benjamini–Hochberg procedure; the secondary outcomes are listed in a logical order for clinicians and not in the order of the P values obtained through the Benjamini–Hochberg procedure (details are provided in Table S7). No P values are provided for outcomes for which the difference was not tested in accordance with the statistical analysis plan.
¶ Photopsia is the sensation of seeing lights, sparks, or colors.
‖ If no blood sample was available at day 2, blood measures were assessed from a day 3 blood sample, if available. If no blood sample was available from day 2 or 3, blood measures were assessed from a day 1 blood sample, if available. Data on the urea nitrogen level at postpartum day 2 were not available for 160 women in the tranexamic acid group and 170 women in the placebo group, and data on creatinine at postpartum day 2 were not available for 173 women and 182 women, respectively.
** In the tranexamic acid group, 7 women had pelvic-vein thromboses (ovarian vein in all cases), and 1 a central venous catheter in the internal jugular vein and subsequent thrombosis of this catheterized vein. In the placebo group, 1 woman had a pulmonary embolism and pelvic-vein thrombosis (left ovarian and renal veins), and 1 a deep-vein thrombosis in both legs.
†† The denominator (2049) differs from the numerator of the item “Completed interviews at 3 months” (2047) because 2 women had deep-vein thrombosis during the delivery hospitalization but did not complete the interview at 3 months.
‡‡ In the tranexamic acid group, 1 woman with preexisting diabetes mellitus treated with insulin-pump therapy had seizures at postpartum day 2 in the context of severe hypoglycemia. In the placebo group, 1 woman who had severe immediate postpartum hemorrhage had seizures at postpartum day 12. The clinical examinations, computed tomographic scans of the head, and electroencephalograms were normal in both women, and they received no additional treatment.
was approximately 100 ml); this difference resulted from a significantly smaller decrease in hematocrit from before surgery to after surgery in the tranexamic acid group than in the placebo group. Nonetheless, the clinical relevance of this narrow difference is questionable since there were no significant between-group differences in the secondary clinical outcomes. Our results contrast with findings of meta-analyses of summary data from small, single-center, randomized trials, which have shown that tranexamic acid administration at cesarean delivery resulted in significantly less mean gravimetrically estimated blood loss, as well as in less frequent blood loss exceeding 500 ml and 1000 ml, less frequent use of additional uterotonic agents, and less frequent transfusions than placebo or no treatment (45 to 75% lower risk with tranexamic acid).34–37 Nonetheless, meta-analyses of small trials are prone to biases, especially publication bias; positive findings in small trials are often not substantiated by subsequent large, randomized trials.38

As in the first TRAAP trial15 and in meta-analyses of randomized trials involving women undergoing cesarean delivery,34,35,37 nausea or vomiting occurred significantly more frequently in the tranexamic acid group than in the placebo group. As in these previous trials, the incidence of thromboembolic events during the 3 months after delivery did not differ significantly between the groups, but these events were uncommon, and power to detect differences was limited; the point estimate of the adjusted risk ratio and its 95% confidence interval (4.01; 95% CI, 0.85 to 18.92) are consistent with a wide range of plausible differences in the incidence of venous thromboembolic events, ranging from 15% lower to 18.92 times higher. This finding calls for caution, given the recent report of a significant, almost doubled risk of these events associated with tranexamic acid (with 4 g given over a period of 24 hours, a higher dose and longer duration than were used in our trial) in patients with gastrointestinal bleeding.39

Our trial included a large population of women who underwent cesarean delivery, and one third of these procedures were performed during labor; our trial also had few exclusion criteria. The results are thus likely to be generalizable to women who undergo cesarean delivery in a similar context of care. Blood loss for the primary outcome was assessed with an objective, validated calculation that was based on postoperative and preoperative hematocrit; the latter value was measured at most 8 days before delivery in order to standardize the timing of measurement and avoid heterogeneity due to possible third-trimester changes. The calculated volume of blood loss was similar to the gravimetrically estimated volume of blood loss in both groups. We excluded women who had hemoglobin levels below 9 g per deciliter to reduce the likelihood of postpartum transfusion in the absence of clinically significant blood loss.

This trial had some limitations. It was not powered to detect potentially meaningful differences in the risk of severe maternal complications, such as transfusion. The incidence of the primary outcome was twice as high as expected, a finding that may be related to the inclusion of cesarean deliveries performed during labor. One quarter of the women did not receive tranexamic acid or placebo within the 3 minutes after delivery as specified in our protocol. The per-protocol analyses provided results similar to those in the intention-to-treat analyses, although they are subject to bias because these analyses do not reflect a comparison of randomized groups. Although maternal satisfaction at day 2 and psychological status at 2 months were assessed, more subtle health dimensions, such as quality of life or mother–infant relationship, were not explored.

Among women who underwent cesarean delivery and received a prophylactic uterotonic agent, tranexamic acid administration resulted in a significantly lower incidence of calculated estimated postpartum blood loss greater than 1000 ml or red-cell transfusion by day 2 than placebo but did not result in significantly less common blood loss–related secondary clinical outcomes.

Supported by a grant from the French Ministry of Health under its Clinical Research Hospital Program (PHRC-15-0011). Dr. Sentilhes reports receiving lecture fees from Bayer, GlaxoSmithKline, and Sigvaris and lecture fees and consulting fees from Ferring Pharmaceuticals; Dr. Haddad, receiving consulting fees from Roche Diagnostics France; and Dr. Daniel, receiving consulting fees from LFB Biomedicaments. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the women who participated in the trial; the staff from the participating maternity units: Angers University Hospi-
tal, Bicêtre University Hospital, Besançon University Hospital, Bordeaux University Hospital, Caen University Hospital, Centre Hospitalier Inter-Communal de Créteil University Hospital, Clermont-Ferrand University Hospital, Marseille Saint Joseph Hospital, Marseille University Hospital, Montpellier University Hospital, Nancy University Hospital, Nantes University Hospital, Nièmes University Hospital, Necker-Enfants Malades Hospital, Paris Saint Joseph Hospital, Poissy/Saint-Germain Hospital, Port-Royal Maternity University Hospital, Saint-Etienne University Hospital, Robert Debré University Hospital, Rouen University Hospital, Saint-Etienne University Hospital, Schiltigheim University Hospital, Strasbourg University Hospital, Tours University Hospital, Toulouse University Hospital, and Trussau University Hospital; the members of the independent safety monitoring committee: Cyril Huisouden (chair), Sophie Alexander, Hawa Keita-Meyer, and Sophie Gautier; the clinical research assistants, particularly Aurélie Darmaillacq, Aline Bibles, Melissa Charvet, Fatima-Zahra Makhoukhi, Laure Estève, and Elodie Labbé, as well as the members of the Department of Clinical Research and Innovation of the Bordeaux University Hospital who worked on this trial; Jérôme Galet, Bellabes Ghezzoul, Sébastien Marchi, Anne Gimbert, and Jonathan Belcastro; and Jo Ann Cahn for her help in editing an earlier version of the manuscript.

APPENDIX

The authors' full names and academic degrees are as follows: Loïc Sentilhes, M.D., Ph.D., Marie V. Sénat, M.D., Ph.D., Maëla Le Lous, M.D., Norbert Winer, M.D., Ph.D., Patrick Rozenberg, M.D., Ph.D., Gilles Kayem, M.D., Ph.D., Eric Verspuyck, M.D., Ph.D., Florence Bretelle, M.D., Ph.D., Sophie Regueme, Ph.D., Caroline Roussillon, M.D., Mottet, M.D., Ph.D., Guillaume Legendre, M.D., Ph.D., Vincent Letouzey, M.D., Ph.D., Bassam Haddad, M.D., Ph.D., Delphine Vardon, M.D., Hugo Madar, M.D., Aurélien Mattuizzi, M.D., Valérie Daniel, Pharm.D., Sophie Regueme, Ph.D., Caroline Roussillon, M.D., Antoine Benard, M.D., Ph.D., Aurore Georges, M.Sc., Astrid Darsonval, Pharm.D., and Catherine Deneux-Tharaux, M.D., Ph.D.

The authors' affiliations are as follows: the Department of Obstetrics and Gynecology (L.S., H.M., A.M.), the Department of Clinical Research and Innovation (S.R.), and the Euclid–French Clinical Research Infrastructure Network (S.R.), and the Euclid–French Clinical Research Infrastructure Network (F-CRIN) Clinical Trials Platform, M.D., Hugo Madar, M.D., Aurélien Mattuizzi, M.D., Valérie Daniel, Pharm.D., Sophie Regueme, Ph.D., Caroline Roussillon, M.D., Antoine Benard, M.D., Ph.D., Aurore Georges, M.Sc., Astrid Darsonval, Pharm.D., and Catherine Deneux-Tharaux, M.D., Ph.D.

REFERENCES

9. The CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised,